The global gene therapy market was valued at USD 3.61 billion in 2019 and is projected to reach USD 35.67 billion by 2027, growing at a robust compound annual growth rate (CAGR) of 33.6%. In 2019, the United States led the global landscape, accounting for 59.83% of the total market share.

The gene therapy market is gaining significant traction globally, driven by the rising prevalence of genetic disorders, advancements in gene-editing technologies, and growing interest in personalized medicine. Gene therapy offers promising solutions for previously untreatable diseases by targeting the root cause at the genetic level. With increasing regulatory approvals and robust investment in research and development, the gene therapy market is poised for substantial growth. Despite challenges such as high treatment costs and regulatory complexities, the market continues to expand across key regions, especially in North America and Asia Pacific. As innovation progresses, the gene therapy market is expected to play a transformative role in the future of healthcare.

Continue reading for more details:

**https://www.fortunebusinessinsights.com/industry-reports/gene-therapy-market-100243**

Market Segmentation

• By Therapy Type: Includes in vivo gene therapy and ex vivo gene therapy.
• By Vector Type: Categorized into viral vectors (e.g., adenovirus, lentivirus, AAV) and non-viral vectors (e.g., plasmid DNA).
• By Indication: Covers cancer, neurological disorders, cardiovascular diseases, inherited genetic disorders, and others.
• By End User: Divided into hospitals, specialty clinics, and research & academic institutions.

List Of Key Companies Profiled in Gene Therapy Market:

• Novartis AG
• Spark Therapeutics, Inc.
• Biogen
• Gilead Sciences, Inc
• Amgen, Inc.
• Jazz Pharmaceuticals, Inc.
• Sarepta Therapeutics
• GlaxoSmithKline plc
• Other Prominent Players